First National Advisers LLC Reduces Stock Holdings in United Therapeutics Corporation $UTHR

First National Advisers LLC reduced its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 24.8% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 6,269 shares of the biotechnology company’s stock after selling 2,064 shares during the period. First National Advisers LLC’s holdings in United Therapeutics were worth $3,054,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Torren Management LLC purchased a new stake in shares of United Therapeutics during the 4th quarter valued at about $26,000. Activest Wealth Management increased its holdings in United Therapeutics by 1,400.0% during the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 56 shares during the last quarter. Wilmington Savings Fund Society FSB boosted its stake in shares of United Therapeutics by 125.6% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after buying an additional 49 shares during the last quarter. Harbor Capital Advisors Inc. purchased a new position in shares of United Therapeutics during the 4th quarter valued at approximately $48,000. Finally, Legacy Wealth Managment LLC ID boosted its stake in shares of United Therapeutics by 284.6% during the 4th quarter. Legacy Wealth Managment LLC ID now owns 100 shares of the biotechnology company’s stock valued at $49,000 after buying an additional 74 shares during the last quarter. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, EVP Paul A. Mahon sold 8,300 shares of the business’s stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $586.75, for a total value of $4,870,025.00. Following the completion of the sale, the executive vice president directly owned 45,172 shares in the company, valued at approximately $26,504,671. The trade was a 15.52% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Martine A. Rothblatt sold 9,500 shares of the business’s stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $564.95, for a total value of $5,367,025.00. Following the completion of the sale, the chief executive officer owned 40,513 shares of the company’s stock, valued at $22,887,819.35. This trade represents a 19.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 482,155 shares of company stock worth $266,844,149. 8.60% of the stock is currently owned by insiders.

Analyst Ratings Changes

UTHR has been the subject of several research analyst reports. Cantor Fitzgerald increased their target price on United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research note on Thursday, March 12th. HC Wainwright increased their target price on United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research note on Tuesday, March 31st. Jefferies Financial Group reiterated a “buy” rating on shares of United Therapeutics in a research note on Monday, March 2nd. Morgan Stanley set a $516.00 target price on United Therapeutics in a research note on Thursday. Finally, TD Cowen increased their target price on United Therapeutics from $575.00 to $660.00 and gave the company a “buy” rating in a research note on Monday, March 30th. Eleven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, United Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $619.42.

United Therapeutics Trading Up 0.9%

Shares of NASDAQ UTHR opened at $569.88 on Tuesday. United Therapeutics Corporation has a twelve month low of $272.12 and a twelve month high of $609.35. The company has a market capitalization of $24.19 billion, a price-to-earnings ratio of 21.04, a price-to-earnings-growth ratio of 1.80 and a beta of 0.60. The business has a 50 day simple moving average of $552.09 and a 200-day simple moving average of $503.34.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The firm had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. During the same quarter last year, the firm posted $6.63 earnings per share. United Therapeutics’s revenue was down 1.6% compared to the same quarter last year. As a group, equities analysts predict that United Therapeutics Corporation will post 27.4 earnings per share for the current year.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.